Wednesday, July 8, 2026

pharma · Vascular Dementia · Angioimmunoblastic T-cell Lymphoma · NBP

NovaBridge Biosciences

NovaBridge Biosciences clinical programs — 3 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Rockville, USA HQ
2016 Founded
26 Employees
Public company Type
NBP · NYSE Ticker
Company details
Status
Public
HQ
Rockville, USA
Founded
2016
Employees
26
Programs
4
Drugs
7
Patents
0
Intelligence · Clinical Programs

NovaBridge Biosciences projects

3 ClinicalTrials.gov programs sponsored by NovaBridge Biosciences.

NovaBridge Biosciences has 3 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Clinical programs

  1. NBP Softgel Capsules

    NovaBridge Biosciences

    AIS

    phase 2 small molecule completed

    1 trial
  2. Placebo

    NovaBridge Biosciences

    Breast Cancer

    phase 2 small molecule terminated

    1 trial
  3. mitoxantrone liposome 16 and azacitidine

    NovaBridge Biosciences

    Angioimmunoblastic T-cell Lymphoma

    phase 2 small molecule active

    1 trial

Frequently asked questions

How many clinical projects does NovaBridge Biosciences have?

3 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.